| INTRODUCTION
Direct-acting antivirals (DAAs) have revolutionised the treatment of hepatitis C virus (HCV) infection, with very high rates (>90%) of sustained virological response (SVR) and good safety profile, also in the advanced stages of disease. 1 However, data on the benefit of viral eradication after DAAs on disease progression and liver-related complications in cirrhotic patients are still limited. 2, 3 In this scenario, of interest is the clinical impact of SVR on the risk of hepatocellular carcinoma (HCC) recurrence. This is a controversial topic [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] where evidence is limited and sometime contrasting, because these limitations are the results of different issues. First, since current DAAs are the accepted standard of care even in patients with previously treated HCC, randomised controlled trials (RCTs) comparing DAAs to placebo are unethical and unfeasible. Second, the benchmark for indirect comparisons of the benefit of HCV eradication by DAAs on HCC recurrence risk has been recently provided by a meta-analysis. 16 However this last one showed that HCC early recurrence risk in HCV-untreated patients with early (Barcelona Clinic Liver Cancer stage 0 or A-BCLC 0/A) HCC stage, who achieved complete radiological response (CRR) after curative treatment, was extremely heterogeneous ranging between 0% and 12.5% at 6th month and 4.9%-62.5% at 12th month. Moreover, study-level and patient-level variables were not able to fully explain the great deal of heterogeneity of the reported HCC early recurrence rates. Therefore, the results of published studies remain inconsistent and the overall assessment of the HCV eradication on HCC recurrence risk is difficult to evaluate. Specifically, two small retrospective observational reports 4, 5 suggested that treatment with DAAs could increase the risk of HCC early recurrence in HCV-related cirrhotic patients with previously cured HCC, while other studies did not confirm this harmful effect. [6] [7] [8] [9] The high clinical, biological and epidemiological heterogeneity of successfully treated HCC, and several methodological weaknesses of retrospective uncontrolled studies, could explain the heterogeneity and the discrepancy among the obtained results. In fact, evaluating the risk of HCC recurrences after DAAs, it is affected by several biases, as consequence of the high variability in available data as to: (1) the design of study, retrospective or prospective, (2) inclusion criteria, (3) baseline patients and tumour characteristics, (4) type of curative HCC treatment, (5) assessment of CRR, (6) HCC recurrence definition (early or late and local or distant), (7) time frames between tumour cure and DAA therapy and between last assessment of tumour response and DAA therapy and (8) history of prior successfully treated HCC recurrences before DAA therapy.
We aimed to assess the risk of HCC early recurrence after DAA therapy in a large prospective cohort of DAA-treated HCV-cirrhotic patients with previous successfully treated early HCC, also looking for factors affecting the risk of HCC early recurrence. 
| Statistical analyses
Experienced medical personnel collected data. Continuous variables were expressed as means AE SDs while categorical data were reported as counts and percentages. The Kaplan-Meier method was used to estimate time to recurrence (TTR) from the inception point (ie, beginning of DAA treatment). Log-rank testing assessed differences in TTR. Potential variables were evaluated as predictors of HCC recurrence. All baseline variables reported in Table 1 were evaluated as potential risk factors for HCC early recurrences by univariate analysis. Variables with P ≤ .10 by univariate analyses were included in the final multivariate Cox model.
Moreover, to avoid the effect of co-linearity with the single variables, MELD, BCLC and Child-Pugh scores were not included in the same multivariate model.
For all analyses, P ≤ .05 were considered statistically significant.
All P values were two-tailed and all confidence intervals (CIs) were
95%. The R Statistical Computing Environment (R Foundation for
Statistical Computing, Vienna, Austria) was used to perform analyses and plot results.
The RESIST HCV regional network was founded by an unrestricted grant of MSD, Gilead, AbbVie and Bristol-Myers Squibb.
This investigator-driven study was entirely founded by the involved hospitals, and was approved by the hospital's ethics committee.
3 | RESULTS Table 1 shows the baseline characteristics of included patients. All the 143 included patients had a BCLC 0/A HCC who showed CRR after resection, thermal ablation or chemoembolization. The mean age was 70.4 AE 9 years and most patients were male (86%).
| Baseline features of patients
Eighty-six per cent of the patients were in Child-Pugh class A, Figure 1 ).
We did not find any significant difference (P = Figure S1 ) (P = .814). Table 3 shows predictors of HCC recurrence by univariate analysis.
| Predictors of HCC recurrences
No significant differences were observed when patients were stratified according to baseline Child-Pugh class (class A, n = 123 patients;
class B, n = 20 patients; P = .153) ( Figure S2 ) and MELD score (≤8, n = 50 patients; >8, n = 93 patients; P = .083) ( Figure S2 ). Main tumour size (HR 2.73; 95% CI 1.23-6.06; P < .014) and history of prior HCC recurrence (HR 2.22; 95% CI 1.02-4.83; P = .043) were independent predictors of HCC recurrence by multivariate Cox model (Table 3 ).
The discriminating ability of the model in predicting HCC recur- 
| DISCUSSION
In this large prospective study, we found that 6-month and 1-year probability of HCC early recurrence after DAA therapy were 12% and 26.6% respectively. Previous history of HCC recurrence and tumour size were the only two independent risk factors for HCC early recurrence. during/after DAAs, using a ''pseudo survival curve" rather than Kaplan-Meier method. 6 Therefore, for the first time to the best of our knowledge, our study assessed HCC early recurrence after DAAs in a large prospective cohort, by actuarial method.
In this complex scenario, the HCC early recurrence rate observed in this study was comparable-and not increased-to that estimated both by meta-analyses, in 701 patients untreated for HCV, 16 and in 226 patients treated with IFN-based therapy ( Figure S1 ). Our study also showed that 17% of the HCC recurrences had an infiltrative pattern, like data by Reig et al. 4 Furthermore, long-term prospective studies are necessary to better substantiate the benefit of SVR on liver decompensation and death. Consistently, we recently demonstrated that hepatic decompensation, not HCC early recurrence, is the major driver of death in patients untreated for HCV with successfully treated HCC. 19 The association between tumour size and HCC early recurrence, observed in our study confirms previous observations from individual studies 20, 21 and meta-analysis. 16 Moreover, it is biologically plausible that the risk of cancer recurrence is higher in patients who already 
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